In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...

Dr. Liang previously worked at Novo Nordisk, where he lead global clinical development and regulatory submission for ...

FHD-909 is an oral, first-in-class allosteric small molecule selectively inhibiting SMARCA2 (BRM) ATPase over SMARCA4 (BRG1), both central catalytic subunits of BAF chromatin-remodeling complexes.

Novartis secured an exclusive worldwide license to Abogen’s Abo2203 and options on additional RNA-platform programs, positioning mRNA-encoded biologic expression as a scalable autoimmune therapeutic ...

Along with rising sales, GLP-1s are a major focus for R&D teams. Major pharma companies are developing new versions of the medication that are easier for patients to use, while al ...

FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...

Four long-acting antibodies will be jointly advanced, targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13, extending type 2 ...

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions ...

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs ...